Investing.comDoubao · 实盘不做把握 7/10不做原因:风险收益比不佳
北京时间·🕒 发布 09:40:30·⟳ 抓取 09:41:04 +34s·⚡ 决策 10-09 09:42:15 +1m11s·18.5 天前
Retension Pharmaceuticals 将IPO定价为每股12美元，募资4500万美元并以RTSN登陆纳斯达克
IPO定价本身是预期内的程序性事件，标的为无营收、无历史定价的4500万美元微型临床期biotech；仅凭上市消息做多首日或做空均不具备正期望，关联方赛诺菲亦无实质敞口。
📄 原文Investing.com↗ 原文
Retension Pharmaceuticals prices IPO at $12 per share
By Investing.com Advertisement Advertisement Retension Pharmaceuticals prices IPO at $12 per share Company News Publish…
不做 Retension Pharmaceuticals, Inc.（RTSN.US）
4500万美元微型临床期biotech首日挂牌，IPO定价为预期内程序事件、无临床/商业新增预期差，无历史价格与可靠先例，追涨或做空均无正期望edge。
不做 Sanofi S.A.（SNY.US）
仅为RTN-001许可方，该小额IPO对赛诺菲收入、利润与市值无可量化重大性，不构成交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Retension以12美元定价、募资4500万美元并首日挂牌，资金用于RTN-001的2b/3期临床；但微型临床期biotech首日表现高度投机，IPO定价不构成可量化的基本面预期差，赛诺菲许可关系亦无重大性，故回避。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 medium ↗
关键理由
- IPO按此前区间完成定价属程序性落地，未释放临床或商业层面的新增正向事实，缺乏短线可交易edge。
主要风险
- RTSN首日可能受生物科技IPO情绪推动大幅波动，但缺乏基本面锚点，追高或抄底均承担高偶然性与低流动性风险。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
公司为临床阶段、无产品营收，核心药仍在2b期、距3期与商业化遥远，IPO定价不含临床或监管正向surprise。
检索:Retension Pharmaceuticals RTSN IPO risks RTN-001 clinical trial hypertension 原文 ↗
先例如何影响了这次决策
对本次决策的影响:因缺乏高相似先例且事件本身为程序性定价，直接支持回避，不给出任何方向的ENTER。
方向:无可直接对照的同主体先例；微型临床期biotech IPO首日方向高度依赖市场情绪，不具稳定方向。
涨幅量级:缺乏同市场、同规模且锚定IPO定价日的干净先例，不用任何臆测幅度设定止盈止损。
形态:未检索到足以支撑统计结论的样本，不能假设新股必涨或见光死。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 19 ms
{"result": "search_processed_events:agent query=`retension pharmaceuticals 45 million nasdaq capital market offering rtn-001 | retension pharmaceuticals rtsn ipo pricing $12 per share`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。
原文全文
展开原文 · 7,242 字
Retension Pharmaceuticals prices IPO at $12 per share By Investing.com
Advertisement
Advertisement
Retension Pharmaceuticals prices IPO at $12 per share
Company News
Published
Oct 08, 2026, 09:40 PM
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
© Reuters
In this article:
RTSN
0.00%
FALLS CHURCH, Va. -
Retension Pharmaceuticals
, Inc. (
NASDAQ:RTSN
) priced its initial public offering on Wednesday at $12.00 per share, according to a press release statement.
The clinical-stage biopharmaceutical company sold 3,750,000 shares in the upsized offering, generating expected gross proceeds of $45.0 million before deducting underwriting discounts and other expenses. The company granted underwriters a 30-day option to purchase up to 562,500 additional shares at the offering price.
Trading is expected to begin today on the Nasdaq Capital Market under the ticker symbol RTSN. The offering is scheduled to close on October 13, 2026, subject to customary closing conditions.
Retension stated it intends to use the net proceeds, along with existing cash and cash equivalents, to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension and to prepare for a planned Phase 3 clinical trial of the same drug. Remaining funds will be allocated to general corporate purposes and operating expenses.
The company focuses on developing medicines for hypertension and other cardiovascular diseases. Its lead candidate, RTN-001, is a PDE5 inhibitor in development for patients with uncontrolled and resistant hypertension. The drug has been studied in multiple clinical trials involving 265 enrolled subjects.
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are serving as joint bookrunning managers for the offering, with Titan Partners acting as lead manager.
Registration statements relating to the securities became effective on October 8, 2026. RTN-001 is being developed under an exclusive worldwide license from Sanofi S.A.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,306.70
+75.0
+0.15%
US 500
7,776.70
+11.2
+0.14%
Dow Jones
51,231.64
+51.77
+0.10%
S&P 500
7,765.36
-36.41
-0.47%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.41
+0.33
+2.19%
Dollar Index
101.805
-0.125
-0.12%
Crude Oil WTI Futures
90.82
-0.67
-0.73%
Brent Oil Futures
103.43
-0.85
-0.82%
Natural Gas Futures
3.132
-0.038
-1.20%
Gold Futures
4,195.05
+38.05
+0.92%
Silver Futures
60.258
+0.837
+1.41%
Copper Futures
6.6203
+0.0503
+0.76%
US Soybeans Futures
1,295.75
+8.25
+0.64%
U.S. 10Y
5.219
-0.010
-0.19%
U.S. 30Y
5.605
-0.002
-0.04%
U.S. 5Y
4.98
-0.011
-0.22%
U.S. 3M
4.161
+0.010
+0.24%
US 10Y T-Note Futures
104.77
+0.05
+0.04%
Euro Bund Futures
121.23
+0.56
+0.46%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Nasdaq ends over 1% lower as tech stocks take a hit on OpenAI revenue report
By Investing.co
...
Oct 09, 2026
Oil settles below session high after Trump says no Iran attack before midterms
By Investing.co
...
Oct 09, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
TSMC Blowout Earnings: What This Means for Markets
By Lee Yang
Oct 09, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.84
-4.79%
29.91M
NVDA
230.48
-2.94%
118.70M
SNDK
1,609.46
-4.90%
9.36M
AMD
620.68
-3.90%
23.49M
INTC
107.08
-5.34%
120.20M
AAPL
340.42
+1.11%
35.33M
META
720.89
-0.06%
16.04M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.47M
CMG
32.68
+6.21%
72.04M
GDDY
103.19
+6.15%
1.83M
ACN
208.36
+5.96%
12.10M
IT
195.41
+5.19%
919.83K
CTSH
60.01
+5.15%
9.93M
EPAM
113.86
+5.11%
847.63K
Name
Last
Chg. %
Vol.
ALAB
347.05
-9.21%
6.45M
CRWV
81.58
-7.77%
42.32M
NBIS
219.71
-7.35%
21.97M
ARM
275.29
-6.48%
6.20M
GLW
152.83
-6.38%
9.05M
VST
156.14
-6.35%
11.32M
LITE
1,048.60
-5.62%
4.88M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.84
-4.79%
29.91M
NVDA
230.48
-2.94%
118.70M
SPCX
160.57
-4.19%
71.90M
SNDK
1,609.46
-4.90%
9.36M
PLTR
198.78
+2.40%
41.87M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Retension Pharmaceuticals prices IPO at $12 per share
Company News
Published
Oct 08, 2026, 09:40 PM
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
© Reuters
In this article:
RTSN
0.00%
FALLS CHURCH, Va. -
Retension Pharmaceuticals
, Inc. (
NASDAQ:RTSN
) priced its initial public offering on Wednesday at $12.00 per share, according to a press release statement.
The clinical-stage biopharmaceutical company sold 3,750,000 shares in the upsized offering, generating expected gross proceeds of $45.0 million before deducting underwriting discounts and other expenses. The company granted underwriters a 30-day option to purchase up to 562,500 additional shares at the offering price.
Trading is expected to begin today on the Nasdaq Capital Market under the ticker symbol RTSN. The offering is scheduled to close on October 13, 2026, subject to customary closing conditions.
Retension stated it intends to use the net proceeds, along with existing cash and cash equivalents, to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension and to prepare for a planned Phase 3 clinical trial of the same drug. Remaining funds will be allocated to general corporate purposes and operating expenses.
The company focuses on developing medicines for hypertension and other cardiovascular diseases. Its lead candidate, RTN-001, is a PDE5 inhibitor in development for patients with uncontrolled and resistant hypertension. The drug has been studied in multiple clinical trials involving 265 enrolled subjects.
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are serving as joint bookrunning managers for the offering, with Titan Partners acting as lead manager.
Registration statements relating to the securities became effective on October 8, 2026. RTN-001 is being developed under an exclusive worldwide license from Sanofi S.A.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,306.70
+75.0
+0.15%
US 500
7,776.70
+11.2
+0.14%
Dow Jones
51,231.64
+51.77
+0.10%
S&P 500
7,765.36
-36.41
-0.47%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.41
+0.33
+2.19%
Dollar Index
101.805
-0.125
-0.12%
Crude Oil WTI Futures
90.82
-0.67
-0.73%
Brent Oil Futures
103.43
-0.85
-0.82%
Natural Gas Futures
3.132
-0.038
-1.20%
Gold Futures
4,195.05
+38.05
+0.92%
Silver Futures
60.258
+0.837
+1.41%
Copper Futures
6.6203
+0.0503
+0.76%
US Soybeans Futures
1,295.75
+8.25
+0.64%
U.S. 10Y
5.219
-0.010
-0.19%
U.S. 30Y
5.605
-0.002
-0.04%
U.S. 5Y
4.98
-0.011
-0.22%
U.S. 3M
4.161
+0.010
+0.24%
US 10Y T-Note Futures
104.77
+0.05
+0.04%
Euro Bund Futures
121.23
+0.56
+0.46%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Nasdaq ends over 1% lower as tech stocks take a hit on OpenAI revenue report
By Investing.co
...
Oct 09, 2026
Oil settles below session high after Trump says no Iran attack before midterms
By Investing.co
...
Oct 09, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
TSMC Blowout Earnings: What This Means for Markets
By Lee Yang
Oct 09, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.84
-4.79%
29.91M
NVDA
230.48
-2.94%
118.70M
SNDK
1,609.46
-4.90%
9.36M
AMD
620.68
-3.90%
23.49M
INTC
107.08
-5.34%
120.20M
AAPL
340.42
+1.11%
35.33M
META
720.89
-0.06%
16.04M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.47M
CMG
32.68
+6.21%
72.04M
GDDY
103.19
+6.15%
1.83M
ACN
208.36
+5.96%
12.10M
IT
195.41
+5.19%
919.83K
CTSH
60.01
+5.15%
9.93M
EPAM
113.86
+5.11%
847.63K
Name
Last
Chg. %
Vol.
ALAB
347.05
-9.21%
6.45M
CRWV
81.58
-7.77%
42.32M
NBIS
219.71
-7.35%
21.97M
ARM
275.29
-6.48%
6.20M
GLW
152.83
-6.38%
9.05M
VST
156.14
-6.35%
11.32M
LITE
1,048.60
-5.62%
4.88M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.84
-4.79%
29.91M
NVDA
230.48
-2.94%
118.70M
SPCX
160.57
-4.19%
71.90M
SNDK
1,609.46
-4.90%
9.36M
PLTR
198.78
+2.40%
41.87M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
5bf3aac2c3· 2026-10-09 09:42 · doubao / doubao-seed-evolving-latest-version · 策略包d5018cb8913f当前